Version history

{
  "session_id": "sess_hypdebate_SDA_2026_04_16_hyp_d_20260426_153245",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "content": "\n\n## Theoretical Analysis: SASP Modulation in Neurodegeneration\n\n### Key Molecular Mechanisms\n\n**SASP as a Therapeutic Target**\nThe hypothesis proposes that selective modulation of the Senescence-Associated Secretory Phenotype (SASP) offers a nuanced alternative to senescent cell elimination. SASP components—particularly IL-1β, IL-6, and TNF-α—drive neurotoxic inflammation in aging brains (Chinta et al., *Cell Reports* 2015; PMID: 26077868).\n\n**NF-κB as Master Regulator**\nNFKB1 encodes p50/p105, a core NF-κB subunit that orchestrates SASP transcription. Senescent cells show sustained NF-κB activation, creating a feedforward inflammatory loop (Chien et al., *Science* 2011; PMID: 21854231). Critically, NF-κB also regulates BDNF expression in neurons—complete pathway suppression could compromise neurotrophic support.\n\n**The BDNF Paradox**\nBDNF normally supports neuronal survival and synaptic plasticity. SASP-modulating strategies must preserve BDNF production while suppressing pro-inflammatory cytokines. This creates a therapeutic window requiring pathway selectivity rather than broad suppression.\n\n**IL-1β's Dual Role**\nIL-1β serves as both SASP inducer and component, creating potential for intervention at multiple points. However, IL-1β also participates in CNS homeostasis—complete blockade risks unintended consequences.\n\n### Testable Predictions\n\n1. **Selective NF-κB modulation** (targeting p50-containing complexes) will reduce IL-1β/IL-6 secretion by senescent glia while maintaining BDNF expression in neurons—distinguished by chromatin immunoprecipitation showing altered gene promoter occupancy.\n\n2. **SASP modulation** will reduce neurodegeneration markers (phosphorylated tau, α-synuclein aggregation) in rodent models more effectively than senolytic approaches, as measured by longitudinal PET imaging of neuroinflammation using TSPO tracers.\n\n3. **BDNF restoration** in senescent astrocytes will depend on specific NF-κB subunit targeting, with p50 knockout preserving neurotrophic function while p65 inhibition causing BDNF suppression.\n\n### Risks and Limitations"
}